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Citrulline in health and disease 
 
Abstract 1 
The amino acid L-citrulline (CIT) is safely used from the neonatal period onwards in 2 
those with urea cycle defects and carbamyl phosphate synthetase or ornithine 3 
transcarbamylase deficiencies, but several lines of enquiry indicate that it might have a 4 
much wider therapeutic role.  5 
When protein intake is low and there is a catabolic state, endogenous arginine (ARG) 6 
synthesis cannot fully be met and its supplementation can prove challenging, particularly 7 
in patients with critical and multisystem illness.  Supplementary CIT could constitute a 8 
safer but still focused means of delivering ARG to endothelial and immune cells as CIT is 9 
efficiently recycled into these cells and as kidneys can convert CIT into ARG.  Unlike 10 
ARG, CIT is efficiently transported into enterocytes and bypasses liver uptake.  It also 11 
appears to prevent excessive and uncontrolled nitric oxide (NO) production.  Animal 12 
studies and early human data indicate positive effects of CIT on protein synthesis, in 13 
which its contribution is thought mediated through the mTOR pathway.   14 
It apperas that CIT is an anabolic pharmaconutrient that can be safely administered even 15 
in critically ill patients.  Promising results in cardiovascular diseases and in disease-16 
related malnutrition can now be considered sufficient to justify formal clinical exploration 17 
in these areas and in sarcopenia in general.  18 
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Introduction and background 19 
Citrulline (CIT) is an amino acid which is an end product of glutamine metabolism and a 20 
metabolite of arginine (ARG).  21 
Its name is derived from citrullus the Latin name for watermelon. It was extracted in 1914 22 
by Koga&Odake from watermelon(1) and identified by Wada in 1930. Of note, this 23 
aminoacid is not incorporated into proteins(2).  24 
Glutamine is a precursor of ornithine, which can be converted to CIT by the intestine. 25 
Arginine is also metabolized in CIT into enterocytes(2) . Because enterocytes do not 26 
possess argininosuccinate synthase, CIT is released in the portal vein (3). Since there only 27 
small net CIT uptake by the liver(3), in the presence of normal liver function, it enters the 28 
systemic circulation and is then transformed in the kidney to ARG (fig.1). CIT net 29 
production at the whole body level is therefore almost exclusively from the epithelium of 30 
small intestine (Fig 1) (2) . 31 
CIT can act as ARG regulator as it can control delivery of ARG to the liver. Intestinal 32 
arginase and ornithine carbamoyl transferase yield citrulline in proporsion to delivery of 33 
dietary protein. Fasting leads to less CIT and proportionally more ARG reaching liver. 34 
ARG has a major impact on hepatic enzymes and up to 5 fold increase in ureagenesis. 35 
This effect needs to be regulated, hence the important role of CIT in this physiological 36 
context(2,3) 37 
These metabolic considerations explain why administration of CIT has been proposed to 38 
increase systemic ARG concentrations. Of note, CIT is almost absent in food.  Only 39 
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watermelon contains significant amounts of CIT; all parts of watermelon, rind, flesh and 40 
seeds contain CIT in greatest amount, on a dry weight basis in the rind, which might offer 41 
a  convenient source of natural citrulline(4) 42 
In healthy individuals the plasma concentration of citrulline is about 40 µmol/L with 43 
some racial variation (less in Chinese Asians) (5). 44 
CIT plasma concentration has been proposed as clinical tool for identification of small 45 
bowel absorptive mass. Statistical significant correlations between plasma CIT 46 
concentration and small bowel length as well as villous atrophy have been demonstrated. 47 
CIT has been considered a reliable marker of intestinal malabsorption and its role in 48 
clinical practice in currently under investigation(6).  49 
CIT as an organic supplement appears to be a powerful pharmaconutrient, and early 50 
experimental studies have suggested its therapeutic potential to restore ARG metabolism 51 
in critically ill patients with sepsis (7, 8).   52 
CIT exhibits good bioavailability (9), thanks to its ability to be handled by a wide number 53 
of amino acid transporters (10). In the liver CIT is a metabolic intermediate involved in the 54 
elimination of a toxic component (ammonia) through another which is non-toxic (urea) 55 
(Fig.1). Of note, CIT recycling in the urea cycle is mainly separated  meaning that there is 56 
neutral /balanced flux in the liver (3) (Fig 1). The brain and some leukocytes can also 57 
produce ARG from CIT (11) to a limited extent. 58 
Oral CIT supplementation raises plasma ARG concentrations and augments nitric oxide 59 
(NO)-dependent signalling proportionally (12) . Since CIT is not subject to pre-systemic 60 
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elimination in the liver whereas ARG is largely extracted there (13) (Fig. 1) CIT serves as 61 
an ARG precursor more productively than ARG itself (2, 3, 12).   In most human studies, 62 
CIT has been used as a supplement, intending this as a substrate from which ARG can be 63 
synthesized or as a NO precursor.  64 
CIT is indeed one of the key organic compound leading to production of NO in most 65 
cells, NO synthase (NOS) enzymes catalysing the conversion of ARG into CIT, 66 
producing NO in an internally conservative cycle(13) (fig 2).  Although intracellular ARG 67 
concentrations are sufficient to saturate NOS, therapy with excess ARG can enhance NO 68 
production because the CAT-2 ARG transporter is closely associated to NOS within the 69 
cell membrane and both are co-stimulated by signals such as pro-inflammatory cytokines 70 
(3)
. In the situation of low protein intake, it is possible that the alternative pathway is 71 
activated. To inhibit ARG derived ureagenesis and thus loss of proteins, intestinal 72 
arginase and ornithine carbamoyl transferase are activated. This results in an increase in 73 
prehepatic conversion of ARG to CIT, which (unlike ARG) passes more or less freely 74 
through the liver and is released to the systemic circulation(2,13,14).  75 
CIT as dietary supplement appears to be a powerful pharmaconutrient, and early 76 
experimental studies have suggested its therapeutic potential to restore ARG metabolism 77 
in critically ill patients with sepsis (7, 8). 78 
 
79 
Safety of citrulline administration 80 
CIT is considered as safe for oral use (15).  It has no identified toxicity and is used as long-81 
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term replacement therapy for children with urea cycle defects.  In contrast to ARG and 82 
ornithine, which induce gastrointestinal side effects at moderate dosage (e.g. 10g in one 83 
bolus) (16), no side effects have been reported from CIT administration as an oral 84 
supplement at doses up to 15g (9).  Additional safety data come from interventional 85 
studies.  86 
In a randomized placebo-controlled double-blind trial of orally administered CIT in 40 87 
children undergoing repair of congenital cardiac defects no adverse events were noted (17). 88 
In a pharmacokinetic study of intravenously administered CIT no side effects or adverse 89 
events were noted (18). This pharmacokinetic study formed the basis for an on-going 90 
randomized, placebo controlled, double-blind trial of intravenous CIT in children at above 91 
average postoperative risk after surgery for congenital heart disease (19) . 92 
CIT supplementation is now raising clinical interest for the treatment of paediatric 93 
pulmonary hypertension however further controlled clinical trials are needed to drawn an 94 
impactful conclusion (20) . 95 
 96 
Effects on immunity, oxidative stress and related parameters 97 
CIT administration reduces the number of total leukocytes and of neutrophils in 98 
circulation (9) and might induce ARG-derived NO-mediated vasoprotection, with 99 
inhibition of cell adhesion and leukocyte activation, and suppression of endothelial 100 
damage (Fig. 2) (21).   101 
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In red blood cells NO is oxidized to nitrate. Nitrite and nitrate are excreted in the urine. 102 
PRMT (protein arginine methyl transferase) methylate L-arginine in proteins and 103 
methylated proteins are hydrolysed to L-arginine derivate including ADMA (asymmetric 104 
dimethylarginine) that is hydrolysed by DDAH (dimethylarginine 105 
dimethylaminohydrolase) to L-citrulline. CIT acts as scavenger for oxidative lipoproteins 106 
and ADMA(22) (Fig 2). 107 
Citrulline mediated vasoprotection has now been demonstrated in a phase 2 study of 108 
sickle cell disease (23) and further trials are on-going.   109 
As further NO mediated effect with major changes in markers of oxidative stress was 110 
demonstrated by supplementing a group of professional cyclists(21) with a single pre-race 111 
dose of 6g CIT malate. Higher concentrations of neutrophil nitrite suggested that these 112 
effects were mediated by NO (Fig. 2), and there was no evidence of oxidative damage 113 
(levels of malondialdehyde and creatine kinase, for example, remaining normal).  114 
However, there is no definitive evidence that effects of CIT on immunity are mediated 115 
through NO synthesis only. Polyamines derived from ARG and ornithine could also be 116 
involved. Also, CIT has anti-oxidant properties, which could be involved in these effects. 117 
 118 
Effects on sports performance and recovery 119 
In addition to the study reported above (21), several others are of interest in this field. Oral 120 
CIT supplementation given for a week reduced the time needed to complete a cycle 121 
ergometer exercise trial in healthy trained men in a double-blind randomized placebo-122 
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controlled 2-way crossover study (24) CIT supplementation significantly increased plasma 123 
ARG levels and reduced the exercise time by 1.5 % (p < 0.05). This was associated with 124 
subjective improvements in muscle fatigue and ability to concentrate immediately after 125 
exercise.  126 
The effects of CIT on NO biomarkers, pulmonary O2 uptake (V̇O2) kinetics, and exercise 127 
performance were studied in a randomized, placebo-controlled, crossover study. Short-128 
term CIT, but not ARG supplementation can improve V̇O2 kinetics as expressed by V̇O2 129 
mean response time (59 ± 8 and 53 ± 5 s with placebo and CIT respectively, p<0.05) 130 
during severe-intensity exercise, improving the tolerance (duration: 589s ± 101 vs 661s ± 131 
107), and increasing the whole volume of work completed (25).  132 
A further preliminary study suggested that consuming CIT malate before competition has 133 
the potential to improve some elements of performance in masters level female tennis 134 
players (26).  In this lab-based study CIT yielded improved grip strength, peak and 135 
explosive power compared to placebo. Direct application to “on court performance” is 136 
requested to validate results.  137 
A randomized double-blind cross-over study (27) examined the effect of a single 8g dose 138 
of CIT malate on the performance of flat barbell bench presses (pectoral training) as an 139 
anaerobic exercise and to test muscle soreness after this exercise. The study showed a 140 
significant increase in the number of repetitions achieved (52% more in the 4th set than in 141 
the equivalent placebo session where 40mL lemon juice, 10 g powdered sugar, 60 mg 142 
sodium saccharine, and tap water 200 mL were used) and there was a 40% decrease in 143 
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muscle soreness at 24 and 48 hours (27). A further randomized double-blind study (28) 144 
examined the effect of a pre-exercise dose of CIT (6g), watermelon juice (to provide CIT 145 
1g), or placebo (7.5% sucrose placebo drink) on the total number of repetitions completed 146 
over 5 sets, time to exhaustion, maximal oxygen consumption (VO2max), anaerobic 147 
threshold, and flow-mediated vasodilation.  In this study pre-exercise supplementation 148 
appeared to be ineffective in improving exercise performance (28).   149 
It thus appears that CIT may improve exercise performance in young healthy adults under 150 
some conditions, but these acute effects still need further investigation (29).  151 
Of note, in several of these studies, CIT has been used as a malate salt, not as the native 152 
amino acid. As malate is an intermediary of the Krebs cycle increasing cellular energy 153 
production it is unclear whether the observed effects are due to malate, to CIT or to both. 154 
There is no study comparing the effects of CIT malate and CIT.  In Table 2 the doses of 155 
citrulline from citrulline malate have been corrected to subtract the contribution of malate 156 
in those cases where this salt was used. 157 
 158 
MELAS syndrome 159 
As CIT plays a key role in the production of NO in most cells, due to its great ability to 160 
increase intracellular ARG availability, it has been used in children with the 161 
Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) 162 
syndrome (30).  In a recent clinical study stable isotope infusion techniques were used to 163 
assess NO production in children with MELAS syndrome and in healthy controls. In 164 
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children with MELAS syndrome, CIT supplementation resulted in important increases in 165 
NO production, ARG flux, plasma ARG, and CIT flux, which were greater than obtained 166 
with ARG supplementation (31). In an earlier clinical trial (32), the effect of ARG or CIT on 167 
lactic acidaemia had been studied in adults with MELAS syndrome. Plasma lactate 168 
decreased significantly after CIT supplementation, whereas the effect of ARG 169 
supplementation did not reach statistical significance. These promising results justify 170 
additional controlled trials to assess the therapeutic effects of CIT on clinical features and 171 
complications of MELAS syndrome. 172 
 
Cardiovascular diseases 173 
In most of the work in the cardiovascular area, CIT has been given with the intention of 174 
boosting levels of ARG and as a NO precursor.  The conditions studied have therefore 175 
included those where absolute or relative deficiencies of ARG and NO are known or 176 
suspected, and include arteriosclerosis, pulmonary and systemic hypertension and cardiac 177 
failure.  In general, oral CIT is seen to improve cardiac performance with exercise.  A 178 
causal link is supported by the study on professional cyclists already referred to above (19).  179 
In a double-blind, randomized, placebo-controlled trial (33) 15 otherwise healthy middle-180 
aged male subjects with evidence of early arteriosclerosis were given 5.6 g/day of CIT 181 
(n=8) or placebo (n=7) for 7 days.  Their initial arterial stiffness was abnormal, as 182 
indicated by a brachial-ankle pulse wave velocity (baPWV) of >1400 cm/s.  CIT 183 
supplementation increased plasma CIT (p<0.05), plasma ARG (p<0.01), and the ratio of 184 
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ARG to ADMA (p<0.05).  The circulating concentrations of nitrogen oxides (the sum of 185 
nitrite and nitrate) and other metabolic products of NO also rose significantly (p<0.05) 186 
(33)
.  Associated with these biochemical changes there was a clinically significant fall in 187 
the baPWV in the CIT group (p<0.01) with no change in systemic blood pressure, 188 
suggesting the potential for functional improvements in arterial stiffness from CIT 189 
supplementation, independent of blood pressure. 190 
Other studies in patients and in healthy volunteers do however demonstrate effects of CIT 191 
on systemic blood pressure.  In the cold pressor test (CPT), it is normal to see substantial 192 
increases in systemic blood pressure, pulse pressure and a number of other 193 
haemodynamic parameters.  After 4 weeks of daily CIT supplementation (6 g orally) 194 
these effects were all attenuated (each by 4 to 6 mmHg) (34). 195 
Beneficial effects of CIT and ARG on endothelial function are shown by their 196 
normalization of the MAT/TT index in patients with early cardiac failure.  This index is 197 
the ratio of the maximum amplitude time (MAT) on finger plethysmography to the total 198 
time (TT) of the curve.  After 60 days during which 3 g oral CIT malate was given daily, 199 
the basal MAT/TT had fallen from a mean of 41.1 (± 13.47) to 23.6 (± 6.74) (p=0.007) 200 
(where 30 is the upper limit of normal).  Testing was repeated after brief, experimentally 201 
induced, digital ischaemia, and when ARG was given rather than CIT, and in both cases 202 
similar improvements were seen at 60 days (35), which suggests a common mechanism of 203 
action, likely through NO production.  204 
In a second paper (36), on the same patients, the authors recorded the effects of CIT on 205 
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pulmonary artery pressure, which fell by 16% (56.7 ± 7.96 mmHg to 47.7 ± 8.59 mmHg; 206 
p<0.05) over 60 days in association with an improvement in right ventricular ejection 207 
fraction, blood pressure and treadmill tolerance. ARG was equally effective, but required 208 
the higher dose of 8 g (36). This may be explained by the fact that ARG is metabolized in 209 
splanchnic area whereas CIT is not (see above for details). 210 
Another group of investigators recently reported that adults with heart failure had 211 
improvements in left ventricular ejection fraction, functional class, and endothelial 212 
function as assessed by photoplethysmography after treatment with oral CIT for 4 months 213 
(37)
. 214 
Intensive CIT supplementation (oral or intravenous) was previously proposed as a 215 
possible means of preventing post-operative pulmonary hypertension, with a subsequently 216 
suggested target plasma CIT concentration in excess of 37µmol/L (37).  This has been 217 
partially tested in children undergoing surgical procedures for congenital heart lesions.  218 
Oral CIT supplements safely increased plasma CIT and ARG concentrations compared 219 
with placebo, and improved NO production (17).  The expected decreases in plasma CIT 220 
and ARG concentrations after cardiopulmonary bypass seen in the placebo group were 221 
prevented by CIT. This was associated with a decreased risk of postoperative pulmonary 222 
hypertension (15% in those treated with CIT compared to 30% in the controls). It was 223 
thought that this effect was causally derived from the production of L-ARG from CIT, 224 
and to stimulation of NO pathway in the hepatic and pulmonary tissues. The cytosolic 225 
portion of the urea cycle was thought to be enabling localized, intracellular production of 226 
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L-ARG from CIT within the pulmonary endothelium as well as in hepatocytes.  Curiously 227 
these papers, which report on work from more than a decade ago, do not seem to have 228 
been followed-up by their authors or others in the field (38,39). 229 
Electrophysiological mechanisms may also be important.  A study in healthy individuals 230 
given CIT (3.2g 60-90 minutes before testing) demonstrated a reduction in QT interval on 231 
electrocardiography, indicative of a shortening of the time required to de/repolarize the 232 
myocardium (40).  233 
Taken as a whole these results are impressive but most enrolled a limited number of 234 
subjects and only surrogate markers were studied. The time appears ripe for study of 235 
larger cohorts of patients and evaluating the effects of CIT on morbidity and mortality. 236 
 237 
Anabolic effects 238 
Through various underlying mechanisms, CIT has the potential to affect protein 239 
metabolism (41).  Osowska et al (42) showed that when malnourished elderly rats were re-240 
fed with a CIT-enriched diet, muscle protein synthesis was greater, while hepatic protein 241 
synthesis was less than in control rats fed an isonitrogenous supplement of non-essential 242 
amino acids (NEAA).  These data are now being supported by human studies of muscle 243 
protein synthesis (43).  Eight healthy participants were investigated in a crossover study in 244 
which, following 3 days of standardised low protein intake, CIT or a NEAA mixture was 245 
given orally as small boluses over the course of 8 hours. Stable isotopes of phenylalanine 246 
[13C] and tyrosine [15N] were administered as tracers to assess protein metabolism. The 247 
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fractional synthesis rate (FSR) of muscle protein was measured using phenylalanine 248 
enrichment in muscle tissue fluid as the precursor pool.  The FSR of mixed muscle 249 
protein was found to be higher after the period on CIT than when on NEAA (NEAA: 250 
0.049 ± 0.005; CIT: 0.060 ± 0.006; p= 0.03). Muscle mitochondrial protein FSR and 251 
whole-body protein turnover did not differ between the two phases of the study (43).  252 
In a randomized controlled study of 10 healthy subjects, oral CIT supplementation was 253 
associated with a 57% improvement in nitrogen balance at 12 hours (from 683 (±246) to 254 
970 (±187) mmol nitrogen/12 h; p=0.0053 for the comparison with placebo) (15).  255 
In a more recent study (44) on sixty-six healthy volunteers, supplementation with CIT and 256 
reduced glutathione were associated with an improvement in cGMP activity, suggesting 257 
direct effects on muscle protein synthesis and muscle performance.  As in Jourdan’s study 258 
(43)
, in a further study (45) of healthy, well-nourished volunteers, oral CIT could not be 259 
shown to affect whole-body protein kinetics in the post-absorptive state.  260 
Muscle protein synthesis contributes only about 25% of whole body protein synthesis (34) 261 
and an increase of (for example) 20% in muscle protein synthesis would therefore 262 
contribute less than a 7% increment in whole body protein synthesis. Together with 263 
Osowska’s data (42) of lower hepatic protein synthesis rates in rats fed with CIT, this may 264 
explain the apparent lack of a CIT effect at the whole-body level despite a statistically 265 
significant effect on muscle protein synthesis.  Bouillanne et al (46) show, in a prospective 266 
randomized multicentre study, that 3-week’s CIT supplementation (10 g/day) in 29 267 
moderately malnourished elderly subjects led to higher muscle mass and fat free mass, 268 
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and lower fat mass than controls supplemented with NEAA, whereas whole body protein 269 
synthesis was similar in the two groups.  In other words, the effects of CIT on nitrogen 270 
handling are neither ubiquitous nor uniform, and its anabolic effects are likely to be 271 
specific to muscle.  272 
However, in one study (47) of 22 healthy, elderly subjects, an effect of CIT on myofibrillar 273 
protein synthesis was not confirmed. CIT co-ingestion with a low quantity (15 g) of 274 
protein was ineffective in augmenting anabolism compared with NEAA. 275 
Hyperargininaemia was interestingly demonstrated after ingestion of CIT in this study.  276 
The mechanisms of action of CIT begin to be understood.  Data suggest an involvement 277 
of the mTOR (mammalian/mechanistic target of rapamycin) pathway in the effect of CIT 278 
on protein synthesis (41, 48). In general mTOR coordinates protein synthesis and 279 
mitochondrial functions by selectively modulating synthesis of a series of nuclear-280 
encoded mitochondrial proteins as well as by regulating mRNA translation (48). 281 
In addition, it has been shown that NOS activity is necessary for calcium-induced 282 
activation of the Akt pathway (involved in translation initiation and thus muscle protein 283 
synthesis) through a cGMP/PI3K-dependent pathway (49). Nitrite has been shown to 284 
enhance mTOR activity and cell proliferation of myoblasts (50).  CIT has relevance in both 285 
of these contexts.  286 
Conclusion 287 
Exogenous CIT is a potent precursor for ARG and it functions as a donor of NO in many 
clinical contexts.  Its administration appears safe but there are currently few clinical 
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studies from which to draw conclusions on its therapeutic efficacy.  Preliminary data 
indicate that it could be of value in systemic and pulmonary hypertension, in cardiac 
failure, in the management of arteriosclerosis, and in sarcopenia in the elderly (Table 1and 
2). Several new clinical research studies have been designed to address these interesting 
possibilities and are on-going. 
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Table1. L- Citrulline: Interventional studies in humans 
 
 
 
 
 
 
 
 
 
 
 
 
 
References Conditions Effects 
8, 36, 39, 42, 
43 
Protein malnutrition Increases fractional synthesis rate of muscle proteins, 
increases muscle mass and fat free mass, increases 
nitrogen balance 
18-20 Healthy controls Increases muscle performance  
15, 17 Professional athletes Reduces post-exercise oxidative stress 
15, 17, 22, 26 Arteriosclerosis  Improves arterial stiffness, increases NO metabolites, 
decreases lipid oxidation 
27 Hypertension Reduces blood pressure on the cold pressor test 
16 Sickle cell disease Reduces hypertension in crises 
28-30 Cardiac failure Normalizes MAT/TT index, improves right ventricular 
ejection fraction and reduces hypertension  
13, 29, 31 Pulmonary 
hypertension 
Reduces pulmonary artery pressure 
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Table 2. L-Citrulline: Design of human studies  
 
Abbreviations: BD, bis die (twice daily).  In this table the citrulline doses have been corrected to subtract the contribution of   
malate in those cases where citrulline malate was used (15,19,20). 
 
 
 
 
Author References Dose/day Days Subjects Design  
Schwedhelm E 8 0.75, 1.5, 3 g BD 7  20 Double-blind randomized 
placebo-controlled cross over 
Rouge C 11 0.18 g/kg  3 10 Pilot randomized-controlled 
Smith HA  13 9.5g / m2 
 
1 40 Randomized placebo controlled 
Sureda A 15 3.4 g  1 16 Prospective, randomized single 
blinded study 
Waugh WH 16 0.1 g/kg 28 5 Early phase II 
Suzuki T 17 2.4 g 7 22 Double-blind randomized 
placebo-controlled 2-way 
crossover 
Bailey SJ 18 6 g 7 10 Randomized placebo-controlled, 
crossover  
Glenn JM 19 5.3 g 1 17 Double-blind, randomized 
Pérez-Guisado J 20 4.5 g  1 41 Randomized, double-blind, 2-
period crossover 
Morita M  80 mg/day 60 22 Prospective pilot  
Figueroa A 27 6 g/day 28 17 Randomized controlled crossover 
Orea-Tejeda A 28 3g 60 30 Prospective controlled 
Orozco-Gutiérrez JJ 29 3g 60 15 Prospective controlled 
Balderas-Munoz K 30 3g 120 20 Prospective randomized placebo 
controlled 
Jourdan M 36 11 – 24 g 1 8 Randomized cross-over pilot 
Bouillanne O 39 10 g 21 29 Randomized multicentre 
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Abbreviations : ARG L-Arginine; CIT L-Citrulline, GLN Glutamine, NO Nitric Oxide 
Figure 1: Effects of L-Citrulline supplementation 
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Abbreviations: ADMA: asymmetric dimethylarginine; DDAH: dimethylarginine dimethylaminohydrolase; 
DMA: dimethylamine; NOS nitric oxide synthase 
Figure 2: Citrulline and Oxidative Stress 
 
 
